The multimodality MRI staging accuracy for endometrial carcinoma stages I-IV by FIGO2009 were 91.6% (76/83), 91.6% (76/83), 92.8% (77/83), and 97.6% (81/83), respectively.
This is a retrospective study utilizing an institutional database (2008-2016) of stage I-IVendometrial cancer cases that underwent hysterectomy-based surgery.
The platform was applied in samples collected from 157 EC patients (stage I-IV) to verify its clinical utility and to examine the diagnostic and prognostic significance of the analysed biomarkers.
The majority of the studies demonstrated highly significant correlation between DNA index (DI) and survival, in univariate analysis including stages I-IV, and in subgroup analysis of stage I and stage I-II EC.
In a histopathological review of 266 women with stage I-IVendometrial carcinoma, the prognostic significance of uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CCC) of the endometrium was compared with that of ordinary adenocarcinoma and adenoacanthoma.
In a retrospective analysis of 106 cases of endometrial carcinoma stages I-IV (FIGO), the prognostic value of DNA ploidy and nuclear morphometry of tumor cells was evaluated and compared with that of conventional clinical and histopathologic parameters.